Mariner’s Accelerate Diagnostics AXDX Stock Holding History

Mariner’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,907	Closed	-$23.5K	–	2908
2023 Q2	$23.5K	Hold	2,907	–	–	﹤0.01%	2768
2023 Q1	$20K	Buy	+2,907	New	+$17.5K	﹤0.01%	2725

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Chartist Inc Seal Beach, California $160M AUM 15.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TWA

TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Mariner's AXDX Position: Q3 2023 in Review

Mariner sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 2,907 shares — an estimated $23.5K sold.

Mariner first reported a position in AXDX in Q1 2023 and held it in 2 quarters. The position peaked at $23.5K in Q2 2023. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

Mariner reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
Mariner sold 2,907 Accelerate Diagnostics shares in Q3 2023, an estimated $23.5K.
Mariner first reported a position in Accelerate Diagnostics in Q1 2023 and held it in 2 quarters.
Mariner's Accelerate Diagnostics position peaked at $23.5K in Q2 2023.
38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on Mariner's 13F filing for Q3 2023, filed 13 Nov 2023.